Euractiv.com

Minister MacNeill urged the European Commission to bring forward the revised Tobacco Products Directive, she also called for an early agreement on the EU Pharma Package.

Tariffs will trigger some job losses, and impact future investment, but Ireland’s strategic value remains solid - ‘Pharma isn’t ditching Ireland anytime soon.’

Supporting thinning among countries backing 90% cut in greenhouse gas emissions

Empowering Europe’s tech SMEs is essential for digital sovereignty. Nicole Verbeeck talks EuroStacks with Sebastiano Toffaletti, Secretary-General of the European DIGITAL SME Alliance.

Belgium is capitalising on a radiopharmaceutical sector investment boom. Pharma giants are acquiring radioligand therapy companies and expanding research areas.

From Paris to Berlin, actions don’t match the grandiose verbiage.

Due to declining market shares, Nestle is closing two production facilities in Germany

Kazakhstan's wide-ranging reforms have brought new global partnerships and encouraged EU trade. Xhoi Zahmi takes a closer look at its revamped political and economic horizons.

French cognac and armagnac producers fear that high Chinese tariffs could become permanent

Both countries would dispatch a "Franco-British team to Ukraine" to meet with Ukrainian counterparts within “three weeks."

When invoked, the suspension could last up to 60 days at a time, with the possibility of an extension if approved by Parliament.

If DMA, DSA, and AI Act need to be reopened in order to strip out overlapping requirements, then so be it.

The AGRI committee was unanimous in calling farmers the weakest link in the food chain.

One source said that the text over compulsory licensing had become a "poison pill."

It also proposes that pooling agreements among manufacturers for 2025 and 2026 can be agreed until 2027.

"Polish farmers are not used to fallowing land; they are accustomed to making productive use of it."

The two institutions meet on Thursday to attempt to resolve the impasse.

Despite the opposition, the decision will most likely depend on the European People's Party (EPP).

There is an ongoing EPP dispute between the industry and health committees over who will lead the Critical Medicines Act.

It could spark an institutional clash with the Council of the EU which is reluctant about regulations.